Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document

Bueno, José Luis; Alegre, Adrián; López-Villar, Olga; Querol, Sergio; Arroyo, José Luis; Goterris, Rosa; Sureda, Anna; García-Gala, José M.; Amunarriz, Cristina; Albó, Carmen; Fernández‐Fuertes, Fernando; Medina, Laura; Antelo, María Luisa; Blanquer, Miguel; Vallejo, Carlos; Canales, Miguel; Vidales-Mancha, I; Duarte, Rafael F.

doi:10.1038/s41409-019-0716-9

Cited by 7 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most frequent PBSC adverse events is citrate-related hypocalcemia. The preferred anticoagulant for PBSC is a citrate solution usually containing sodium citrate dihydrate 22 g/L, glucose monohydrate 24.5 g/L, and citrate acid monohydrate 8 g/L, namely, ACD-A-Anticoagulant Citrate Dextrose Solution A [102].…”

Section: Management Strategies For Intra-and Peri-procedural Adverse ...mentioning

confidence: 99%

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Prisciandaro,

Santinelli,

Tomarchio

et al. 2024

Cells

View full text Add to dashboard Cite

Achieving successful hematopoietic stem cell transplantation (HSCT) relies on two fundamental pillars: effective mobilization and efficient collection through apheresis to attain the optimal graft dose. These cornerstones pave the way for enhanced patient outcomes. The primary challenges encountered by the clinical unit and collection facility within a transplant program encompass augmenting mobilization efficiency to optimize the harvest of target cell populations, implementing robust monitoring and predictive strategies for mobilization, streamlining the apheresis procedure to minimize collection duration while ensuring adequate yield, prioritizing patient comfort by reducing the overall collection time, guaranteeing the quality and purity of stem cell products to optimize graft function and transplant success, and facilitating seamless coordination between diverse entities involved in the HSCT process. In this review, we aim to address key questions and provide insights into the critical aspects of mobilizing and collecting hematopoietic stem cells for transplantation purposes.

show abstract

Section: Management Strategies For Intra-and Peri-procedural Adverse ...mentioning

confidence: 99%

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Prisciandaro,

Santinelli,

Tomarchio

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

“…Mobilization protocol included granulocyte-colony-stimulating factor (G-CSF) with/without chemotherapy. Plerixafor (0.24 mg/kg) was added to G-CSF in poor mobilizers after the first apheresis on Day 5 of G-CSF or pre-emptively when mobilizing failure was predicted based on low CD34 + peripheral blood counts on Day 4, according to available guidelines [7][8][9].…”

Section: Asct Protocolmentioning

confidence: 99%

“…The infused CD34 + dose was categorized into ≥4 Â 10 6 /kg and <4 Â 10 6 /kg, considering that 4 Â 10 6 /kg is the recommended dose for ASCT [8][9][10][11][12].…”

Section: Asct Protocolmentioning

confidence: 99%

“…As in the previous section, a correlation analysis was first performed for quantitative variables (Table S3) and then categorized. Pre-transplant anaemia increased the time until transfusion independence for both RBC (12 [9.5-21] vs. 7 [0-11]; p < 0.001) and platelets (13 [10-20.5] vs. 11 [9][10][11][12][13][14]; p = 0.028). Similarly, pretransplant thrombocytopenia impacted both times until RBC (10 [6.5-16.5] vs. 6 [0-10]; p < 0.001) and PT (14 [11][12][13][14][15][16][17][18][19][20][21][22] vs. 10 [8-13];…”

Section: Time Until Transfusion Independencementioning

confidence: 99%

“…reflects transfusion independence analysis.Being 60 years of age or older was associated with a longer time until transfusion independence for RBC(10 [5.8-14.3] vs. 7 [0-11]; p = 0.006) and platelets (13[11][12][13][14][15][16][17][18][19] vs. 11[8][9][10][11][12][13][14]; p < 0.001).F I G U R E 1 Transfusion requirement distribution. RBC, red blood cells.Having required plerixafor also resulted in a longer time to transfusion independence for RBC(8.5 [6.3-15.8] vs. 7 [0-11.3]; p = 0.021) and platelets(13.5 [11-18.8] vs. 11[8][9][10][11][12][13][14]; p < 0.001) as well as an infused CD34 + dose <4 Â 10 6 /kg increased time of transfusion dependency for both RBC(9 [0-14] vs. 6 [0-10]; p = 0.011) and platelets (13[10][11][12][13][14][15][16][17] vs. 10 [8-13]; p < 0.001).BEAM conditioning was associated with a longer time until PT independence ( p = 0.003) but did not prolong the time until RBC transfusion independence ( p = 0.081).Having required any RBC transfusion during the 10 days before the infusion was associated with a significant delay in transfusion independence for RBC(15 [6-38] vs. 7 [0-12]; p = 0.002) and platelets (17[11][12][13][14][15][16][17][18][19]…”

mentioning

confidence: 99%

See 2 more Smart Citations

Age, CD34+ cell dose, conditioning and pre‐transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation

Regalado‐Artamendi,

García‐Fasanella,

Medina

et al. 2023

Vox Sanguinis

View full text Add to dashboard Cite

Background and ObjectivesAutologous stem cell transplant (ASCT) is a widely used therapy for lymphoma patients and can nowadays be performed on an outpatient basis. This study aimed to describe transfusion support in lymphoma patients undergoing ASCT and identify increased or prolonged transfusion requirement predictors.Materials and MethodsA retrospective study of all consecutive lymphoma patients undergoing ASCT between 2010 and 2020.ResultsOut of 226 patients, 145 (64%) received red blood cell (RBC) transfusions, whereas all 226 (100%) required platelet transfusion (PT). Transfusions between Day +1 and +30 were higher in patients over 60 (2 [1–4] vs. 2 [0–2] RBC; p = 0.001 and 4 [2–8] vs. 3 [2–4] PT; p < 0.001); patients with pre‐transplant anaemia (4 [2.5–6] vs. 2 [0–2] RBC; p < 0.001 and 5 [3–9] vs. 3 [2–4] PT; p = 0.001); pre‐transplant thrombocytopenia (2 [1–4] vs. 2 [0–2] RBC; p < 0.001 and 4 [3–8.5] vs. 2 [1–3] PT; p < 0.001) or CD34+ cell dose <4 × 106/kg (2 [0–4] vs. 2 [0–2] RBC; p = 0.024 and 4 [2–6] vs. 2 [1–3.5] PT; p < 0.001). RBC transfusion independence was reached later in patients receiving carmustine, cytarabine, etoposide and melphalan (BEAM) (hazard ratio [HR] 1.6; confidence interval [CI] 1.1–2.3) and those requiring RBC before infusion and/or with pre‐transplant anaemia (HR 2.2; CI 1.4–3.4). Age above 60 (HR 1.4; CI 1.0–1.9), BEAM conditioning (HR 1.4; CI 1.0–2.0) and pre‐transplant thrombocytopenia and/or requiring PT before infusion (HR 1.8; CI 1.4–2.5) entailed longer time until PT independence.ConclusionThese four factors (age ≥60 years; BEAM conditioning, CD34+ dose <4 × 106/kg and pre‐transplant cytopenia and/or Day −10 to 0 transfusion) allowed dividing patients into three groups with significant differences between them regarding the time until transfusion independence.

show abstract

Comparison Between Standard and High Dose of G-CSF for Mobilization of Hematopoietic Progenitors Cells in Patients and Healthy Donors

García-García¹,

Cid²,

Carbassé³

et al. 2022

Transfusion Medicine Reviews

View full text Add to dashboard Cite

Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document

Cited by 7 publications

References 22 publications

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Age, CD34+ cell dose, conditioning and pre‐transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation

Comparison Between Standard and High Dose of G-CSF for Mobilization of Hematopoietic Progenitors Cells in Patients and Healthy Donors

Contact Info

Product

Resources

About